← Back to Clinical Trials
Recruiting NCT07311018

NCT07311018 Neuromuscular Electrical Stimulation and Leap Motion-Based Exercises in Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07311018
Status Recruiting
Phase
Sponsor Medipol University
Condition Cerebral Palsy (CP)
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-01-01
Primary Completion 2026-09-15

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 15 Years
Study Type INTERVENTIONAL
Interventions
Leap Motion-Based Exercise ProgramNMESConventional Exercise Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-01-01 with a primary completion date of 2026-09-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cerebral palsy (CP) is a group of disorders resulting from a permanent but non-progressive lesion in the developing brain, which affects the development of movement and posture and may lead to activity limitations. Upper extremity involvement is observed in approximately 60% of children with CP. Abnormal muscle tone, imbalance between agonist and antagonist muscles, spasticity, alignment problems, reduced muscle strength, and impaired motor control are among the upper extremity impairments seen in CP. As a result, hand use is typically affected in a way that negatively influences the performance of daily living activities. Upper extremity functionality and hand use are crucial for participation in daily life and overall quality of life in children with CP. In addition to conventional rehabilitation methods, advances in technology have introduced various new modalities for upper extremity rehabilitation. The aim of the present project is to investigate the effects of Leap Motion-based exercise intervention and Neuromuscular Electrical Stimulation (NMES) on hand functions in children with spastic CP. A total of 30 children aged 6-15 years with a diagnosis of spastic CP and distal upper extremity involvement will be included in the study. To evaluate eligibility according to the inclusion criteria, gross motor function level will be assessed using the Gross Motor Function Classification System (GMFCS); hand skills will be assessed using the Manual Ability Classification System (MACS); upper extremity muscle tone will be assessed using the Modified Ashworth Scale (MAS); and passive wrist extension range of motion (ROM) will be measured using an electronic goniometer. Following eligibility confirmation, baseline assessments will be conducted. At baseline wrist ROM will be measured using an electronic goniometer; selective motor control of the wrist will be assessed using the Selective Control of the Upper Extremity Scale (SCUES); hand functions will be evaluated using the Jebsen-Taylor Hand Function Test; daily hand use will be assessed using the ABILHAND-Kids; and wrist extensor and flexor strength and activation will be evaluated via surface electromyography (sEMG). All participants will then undergo a 4-week routine conventional exercise program (3 sessions per week, 40 minutes per session). At the end of this 4-week period assessments will be repeated (at week 4). Subsequently, the 30 children with CP will be randomly allocated into two groups: the Leap Motion Control group (n = 15) and the NMES group (n = 15). Both groups will receive an 8-week intervention consisting of 3 sessions per week, each lasting 60 minutes (20 minutes of Leap Motion-based exercises or 20 minutes of NMES application, in addition to 40 minutes of conventional exercises). At the end of the 8-week intervention, all assessments will be repeated ( at week 12). For statistical analyses, the Statistical Package for the Social Sciences (SPSS) Version 23.0 for Windows will be used.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of spastic unilateral or bilateral cerebral palsy based on clinical and MRI findings. * Involvement of the distal upper extremity (wrist and/or fingers). * Aged between 6 and 15 years. * No history of botulinum toxin injection or surgical intervention to the upper extremity within the past 6 months. * Gross Motor Function Classification System (GMFCS) levels I-III. * Manual Ability Classification System (MACS) levels I-III. * Upper extremity spasticity corresponding to 0, 1, or 1+ on the Modified Ashworth Scale (MAS). * Passive wrist extension limitation not exceeding 10 degrees. * Ability to follow verbal instructions (mental level reported as "normal" or "mild mental retardation" in the medical record). Exclusion Criteria: * Currently participating in a specific hand rehabilitation program. * Presence of visual or hearing impairment. * History of epilepsy. * Presence of chronic, orthopedic, or systemic conditions that may interfere with participation. * GMFCS levels IV or V. * MACS levels IV or V.

Contact & Investigator

Central Contact

Hande Özlü Erdoğan, MSc, PhD Candidate, PT

✉ handeeozlu@gmail.com

📞 +905367075474

Frequently Asked Questions

Who can join the NCT07311018 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 15 Years, studying Cerebral Palsy (CP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07311018 currently recruiting?

Yes, NCT07311018 is actively recruiting participants. Contact the research team at handeeozlu@gmail.com for enrollment information.

Where is the NCT07311018 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07311018 clinical trial?

NCT07311018 is sponsored by Medipol University. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology